Kiniksa Pharmaceuticals International, plc (KNSA)

NASDAQ: KNSA · Real-Time Price · USD
26.72
-0.05 (-0.19%)
At close: May 8, 2025, 4:00 PM
26.72
0.00 (0.00%)
After-hours: May 8, 2025, 4:00 PM EDT
-0.19%
Market Cap 1.95B
Revenue (ttm) 481.17M
Net Income (ttm) -16.95M
Shares Out 72.97M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE 28.20
Dividend n/a
Ex-Dividend Date n/a
Volume 373,453
Open 26.66
Previous Close 26.77
Day's Range 25.97 - 27.00
52-Week Range 17.38 - 28.15
Beta 0.07
Analysts Strong Buy
Price Target 38.00 (+42.22%)
Earnings Date Apr 29, 2025

About KNSA

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an in... [Read more]

Sector Healthcare
IPO Date May 24, 2018
Employees 315
Stock Exchange NASDAQ
Ticker Symbol KNSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price forecast is $38.0, which is an increase of 42.22% from the latest price.

Price Target
$38.0
(42.22% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Kiniksa Pharmaceuticals: Making Steady Progress

Kiniksa Pharmaceuticals posted strong Q1 results last week, beating expectations and raising 2025 ARCALYST net sales guidance to $590-$605 million, up from $560-$580 million. Analyst firms are optimis...

3 days ago - Seeking Alpha

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory diseas...

8 days ago - GlobeNewsWire

Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Q1 2025 Results Conference Call April 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman...

9 days ago - Seeking Alpha

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $590 - $605 million – – KPL-...

9 days ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at ...

14 days ago - GlobeNewsWire

Big Pipeline Updates From Kiniksa Pharmaceuticals

Big Pipeline Updates From Kiniksa Pharmaceuticals

2 months ago - Seeking Alpha

Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript

2 months ago - Seeking Alpha

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – –...

2 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

– Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 – – KPL-387 Phase 1 single ascending dose data support potential monthly dosing – – Kiniksa cont...

2 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 a...

2 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

– ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – K...

4 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday,...

4 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI H...

5 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London Hea...

6 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chair...

6 months ago - Seeking Alpha

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $410 - $420 million – – Life...

6 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024 at...

7 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo Healthca...

9 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat

Kiniksa Pharmaceuticals surged after the company reported strong second quarter results and increased the full year net sales guidance range for Arcalyst. The strong performance is driven by increased...

10 months ago - Seeking Alpha

Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Q2 2024 Earnings Conference Call July 23, 2024 8:30 AM ET Company Participants Rachel Frank – Head of Investor Relations Sanj K. Patel – Chief...

10 months ago - Seeking Alpha

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $405 - $415 million – –  Abi...

10 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at 8:...

10 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's Disease

– Abiprubart Phase 2b clinical trial in Sjögren's Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations –

10 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative activi...

11 months ago - GlobeNewsWire

Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual G...

1 year ago - GlobeNewsWire